ClinicalTrials.gg
RecruitingNCT06370000REMAIN1Updated Nov 5, 2026

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

A Phase 4 interventional study of Oral Azacitidine in Acute Myeloid Leukemia, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Virginia Commonwealth University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing cc-486 in Leukemia, Myeloid, Acute — 3 open to participants now, 5 under way, none of them phase 3. cc-486 · Leukemia, Myeloid, Acute.

Planned enrollment
12th of 15
12 · median 34
Started
2024
with 1 other
Phase 4
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
1 of 15
Virginia Commonwealth University

Among the 15 studies testing cc-486 in Leukemia, Myeloid, Acute, this one is the 12th largest by planned enrollment, is one of 2 that started in 2024, is the only one in phase 4, and was the 14th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

3 of the 15 studies testing cc-486 in Leukemia, Myeloid, Acute are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cc-486

cc-486: first FDA approval 2020 (ONUREG), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cc-486 in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains

Read the detailed description

This is a non-randomized open-label single institution pilot study that will evaluate the feasibility, toxicity, and efficacy of maintenance oral azacitidine in medically transplant eligible non-FMS-like tyrosine kinase 3 (FLT3) mutated AML patients with a disadvantage in at least 1 of the 5 key Center for Disease Control and Prevention (CDC) defined social determinants of health (SDOH) domains that are preclusive to transplant at time of study enrollment, as identified either by the patient or a member of the healthcare team.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have or cytologically confirmed non-Acute Promyelocytic (APL) FLT3 negative AML and have completed induction and consolidation as defined by the treating physician and must be in complete response (CR), Complete response with partial hematologic recovery (CRh), or Complete response with incomplete count recovery (CRi) at time of study enrollment
  • For patients in CR1, AML disease phenotype must be one that is considered for allo HCT in CR1 (intermediate or high risk by European Leukemia Net (ELN), MRD+ CR, slow clearance of MRD) or any AML phenotype (aside from FLT3+ and APL) in CR2 and beyond
  • Medically eligible for hematopoietic cell transplant (allo HCT) as defined by either: treating physician discretion, transplant physician discretion, or hematopoietic cell transplantation-specific Comorbidity index (HCT-CI) index of 5 or less
  • Age ≥ 18 years
  • Enrollment must occur within 4 months of completion of therapy
  • A patient or staff identified health disparity in 1 of the 5 Centers for Disease Control (CDC) defined social determinants of health (SDOH). This may include financial difficulties, lack of caregiver support, difficulties with medical literacy, rurality, appropriate access to health care, lack of an appropriate allogeneic hematopoietic cell transplant (allo HCT) donor, substance abuse
  • Patient must have adequate organ function defined as: (by Cockroft-Gault formula) greater than or equal to 29 mL/min, total and / alanine transaminase (AST/ALT) ≤ to institutional 2x (except Gilbert's syndrome, which may enroll if \< 2x patient's baseline total bilirubin)
  • (ECOG) 0,1,2,3
  • Ability to take oral medications
  • No history of malabsorption syndrome which, in the investigator's opinion, may inhibit absorption of oral medications
  • Women of must consent to effective during study treatment and at least 6 months following the last dose. Women who are breastfeeding are also excluded
  • Male patients must consent to effective contraception during study and at least 3 months after last dose
  • Ability to understand and the willingness to sign a written document

Exclusion Criteria A patient who meets any of the following exclusion criteria is ineligible to participate in the study.

  • FMS-like tyrosine kinase 3 (FLT3 ITD) or tyrosine kinase domain (TKD) mutation
  • Uncontrolled central nervous system (CNS) involvement
  • History of or allergic reaction to azacitidine or its components
  • Stem cell transplant within previous 3 months prior to initiation of study therapy
  • Uncontrolled intercurrent illness or infection
  • History of prior therapy with oral azacitidine
  • Female patients who are pregnant or intend to donate eggs during the study or for 6 months after receiving their last dose of study drug
  • Male patients who intend to donate sperm during the course of this study or for 3 months after last dose
  • Other for which the patient is currently receiving therapy (except excisable skin cancer)
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk or limit the participant's adherence with study requirements
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Oral Azacitidine

    Starting dose is oral azacitidine 300 mg orally once daily with or without food days 1-14 in a 28-day cycle

    Drug: Oral Azacitidine

Interventions

  • DrugCc-486Studies of Cc-486Cc-486 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.

06

What researchers measure

Primary outcomes

  1. Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains

    The number of participants that complete at least four cycles of protocol therapy

    Time frame: 4 months

Secondary outcomes

  1. Overall survival (OS)

    Number of participants alive at relapse, completion of treatment or removal from study.

    Time frame: 3 months, and up to 2 years

  2. Leukemia Free Survival (LFS) 3 months after beginning of treatment and at relapse, completion of treatment or removal from study

    Number of participants still in remission 3 months after beginning of treatment and at relapse, completion of treatment or removal from study

    Time frame: 3 months, and up to 2 years

  3. Measure rates of measurable residual disease (MRD) negativity

    The number of participants that have negative measurable residual disease (MRD) at 3 months after beginning of treatment, and completion of treatment. MRD will be measured by flow cytometry and by pathologic complete response (PCR) based molecular assay if/when target gene is available on diagnostic specimen.

    Time frame: 3 months, and up to 2 years

  4. Assess whether such an approach may provide an effective bridge to curative intent allogeneic hematopoietic stem cell transplant (alloHCT)

    Number of patients who successfully move on to receive an allogeneic hematopoietic stem cell transplant (alloHCT).

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual patient data. Datasets are available on reasonable request to the author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2024 (actual). Primary completion is estimated for Jan 2028, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 17, 2024
StartActual
Nov 7, 2024
Primary completionEst.
Jan 31, 2028was Jan 2027
CompletionEst.
Jan 31, 2030was Jan 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 31, 2027→Jan 31, 2028
Nov 5, 2026
Study completion
Jan 31, 2029→Jan 31, 2030
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jan 31, 2027→Jan 31, 2028
    Study completion Jan 31, 2029→Jan 31, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06370000
Responsible party
Sponsor
First posted
Apr 17, 2024
Start date
Nov 7, 2024
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Massey IIT Research Operations
Contact
masseyepd@vcu.edu
804-628-6430
Keri Maher, DO
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cc-486

Start the discussion